-
-
-
-
-
-
-
Viatris to sell Biocon Biologics stake for $815 million
-
-
-
-
-
-
-
Viatris to pay up to $335 million to resolve opioid-related claims
-
-
-
-
-
-
-
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
-
-
-
-
-
-
-
Viatris Inc (VTRS) Appoints Rogerio Vivaldi Coelho to its Board
-
-
-
-
-
-
-
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
-
-
-
-
-
-
-
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
-
-
-
-
-
-
-
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
-
1,154,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

